logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002 Intellia Therapeutics ( NTLA ) announced the authorization of its Clinical Trial Application ( CTA ) by the New Zealand Medicines and Medical Devices Safety Authority ( MEDSAFE ) to initiate...

Read More

October 6, 2021

0

A Letter to Subscribers

A Letter to Subscribers The complex brutal circumstances we are currently living in has made it imperative that we communicate with you so that you can understand how we at Prohost Biotech are acting in these difficult times. Current news...

Read More

June 30, 2020

0

Blackstone Announces the Launch of a New Company with Intellia Therapeutics and Cellex Cell Professionals GmbH

Blackstone Life Sciences, Intellia Therapeutics and Cellex Cell Professionals New Company Blackstone ( BX ) announced that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor...

Read More

June 22, 2021

0

Halozyme Therapeutics Good News About Approvals. See Also: Arrowhead Pharmaceuticals Good Trial Results for Liver Diseases  

Halozyme Therapeutics Approvals for DARZALEX ® SC Halozyme Therapeutics ( HALO ) announced that the European Commission ( EC ) has granted Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as...

Read More

June 23, 2021

0

Vir Biotechnology: Promising Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 for Chronic HBV Infection  

Vir Biotechnology Announced Positive Safety Findings from its Ongoing Trials for Chronic HBV Vir Biotechnology ( VIR ) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with...

Read More

June 25, 2021

0

A Novel Immunotherapy Approach for the Treatment of COVID-19

Corvus Pharmaceuticals: FDA Granted IND Application for COVID-19 Trial The United States FDA granted approval of Corvus Pharmaceuticals ( CRVS ) investigational new drug ( IND ) application for a COVID-19 trial. Corvus announced the beginning of the Phase 1 study...

Read More

July 7, 2020

0

IVERIC bio Receives FDA Agreement Under an SPA for GATHER2 Phase 3 Clinical Trial of Zimura®

IVERIC bio GATHER2 Trial of Zimura® for Geographic Atrophy  IVERIC Bio ( ISEE ) announced that it received written agreement from the U.S. FDA under a Special Protocol Assessment ( SPA ) for the overall design of GATHER2, the pivotal...

Read More

July 6, 2021

0

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading global eye health business of  Bausch Health Companies ( BHC ),  and  Clearside Biomedical ( CLSD ) announced that the U.S. FDA approved XIPERE™...

Read More

October 25, 2021

0

The Small Firm Whose Stock Soared in Yesterday's Market

Firms' with COVID-19 Vaccines Stock Performance A look at the stock performance of the COVID-19 vaccine firms that have demonstrated early, promising and even good news regarding their prophylactic effect. The outcome was as follows:    Moderna ( MRNA )...

Read More

July 21, 2020

0

Halozyme Announced Janssen Received U.S. FDA Approval of DARZALEX FASPRO®. See Also: IVERIC bio News

Halozyme Therapeutics Announced US FDA Approval for Janssen Biotech's DARZALEX FASPRO® Halozyme Therapeutics ( HALO ) announced that Janssen Biotech, Inc. (Janssen) received U.S. FDA approval of DARZALEX FASPRO® (daratumumab + hyaluronidase-fihj) in combination with pomalidomide and dexamethasone ( Pd )...

Read More

July 13, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 120
  • 121
  • 122
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy